In that trial, a prime-boost immunization regimen involving priming with a recombinant canarypox virus (vCP1521) encoding the gp120, gag, and protease genes from HIV-1 [2] followed by booster immunizations with the bivalent gp120 subunit vaccine, AIDSVAX B/E [3], [4], provided modest (31%) but statistically significant protection from HIV infection. Here, ITIH4 is linked to HIV infectious disease.